- Home
- HCAC vs OTLK Comparison
HCAC vs OTLK Comparison
Compare HCAC & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCAC | OTLK |
|---|---|---|
| Founded | 2025 | 2010 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 294.9M | 249.6M |
| IPO Year | 2025 | 2016 |
Fundamental Metrics
Financial Performance| Metric | HCAC | OTLK |
|---|---|---|
| Price | $10.13 | $0.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.03 |
| AVG Volume (30 Days) | 104.4K | ★ 3.6M |
| Earning Date | 01-01-0001 | 12-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6,355.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.92 | $0.16 |
| 52 Week High | $10.18 | $2.54 |
Technical Indicators
Market Signals| Indicator | HCAC | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 52.23 | 44.49 |
| Support Level | $10.05 | $0.53 |
| Resistance Level | $10.18 | $0.60 |
| Average True Range (ATR) | 0.01 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 18.18 | 63.44 |
Price Performance
Historical ComparisonAbout HCAC Hall Chadwick Acquisition Corp Class A Ordinary Shares
Hall Chadwick Acquisition Corp is a blank check company.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.